Advertisement
The new Pharmacor report entitled Ulcerative Colitis finds that Humira andgolimumab -- as maintenance therapies -- will drive nearly two-thirds of thegrowth in the ulcerative colitis market in the United States, France, Germany,Italy, Spain and the United Kingdom over the next ten years. Humira andgolimumab will expand treatment options for moderate to severe patients whofail treatment with conventional pharmacotherapies, posing a threat toCentocor/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade. Additionally,the approval of Orencia by 2012 for the treatment of moderate to severedisease as an acute and maintenance therapy, will expand treatment options forpatients who fail treatment with tumor necrosis factor-alpha (TNF-alpha)inhibitors.
Advertisement
"We project golimumab may have an advantage over its predecessors withinthe TNF-alpha inhibitor class-specifically Remicade and Humira-because thedrug is being investigated for both intravenous and subcutaneous delivery,"said Kathryn Benton, analyst at Decision Resources. "However, we expect Humirato outperform golimumab in ulcerative colitis sales due to Humira's earliermarket entry and more well-established long-term safety profile."
The report also finds that the uptake of Shire/Takeda/Giuliani'sLialda/Mezavant/Mezavant XL and its launch in additional countries willcontribute to market growth, owing to the agent's improved dosing convenienceand its premium price compared to currently marketed drugs in its class.Lialda/Mezavant/Mezavant XL, the most recently approved oral 5-aminosalicylate, has launched in the United States, Germany and the UnitedKingdom and is expected to launch in the remaining European markets in late2008.
About Decision Resources
Decision Resources (http://www.decisionresources.com) is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 [email protected]
SOURCE Decision Resources, Inc.
